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Abstract. Background: CD105 is highly expressed on
human activated endothelial cells (ECs), is an important
component of the TGF-β1 receptor complex and is essential
for angiogenesis. CD105 expression is up-regulated in
activated ECs and is an important potential marker for
cancer prognosis. Materials and Methods: In vitro rat
myoblasts transfected with the L-CD105 and S-CD105
transfectants. The transfectants were treated with TGF-β1
for the angiogenesis study. Results: L-CD105 affects cell
proliferation in the presence and absence of TGF-β1, and
inhibits p-ERK1/2, p-MEK1/2 and p-c-Jun in L-CD105
transfectants compared to controls. The induction of
phospho-ERK1/2 following treatment with TGF-β1 remained
significantly lower in L-CD105 transfectants compared to
controls. Conclusion: L-CD105 inhibits the phosphorylation
of ERK1/2, MEK1/2, c-Jun1/2/3, and associated signalling
intermediates. CD105 modulates cell growth and TGF-β1
induced cell signalling through ERK-c-Jun expression.
CD105 (Endoglin) is a 180-kDa homodimeric integral
transmembrane glycoprotein composed of disulphide-linked
90-95 kDa subunits and is a receptor component for TGF-β1
and TGF-β3 (1, 2). It is primarily found on activated
angiogenic endothelial cells (ECs) of microvessels of cancer
and numerous other angiogenic diseases (3-8). CD105
regulates a wide range of cellular and physiological
responses, including embryonic development, homoeostasis,
wound healing, chemotaxis, cell proliferation, differentiation,
adhesion, migration, and apoptosis (4, 9-11). Over-
expression of CD105 modulates TGF-β signalling by
interacting with TGF-β receptor I (TGF-β RI) and/or TGF-
β receptor II (TGF-β RII) on CD105 transfected L6E9 cells
and human vascular smooth muscle cells through mitogen-
activated protein kinases (MAPKs) (12, 13) and small-
mothers-against-decapentaplegic (Smad) proteins (14, 15).
Since CD105 overexpression was previously shown to be a
marker of poor cancer outcome (16), and the phosphorylated
ERK is a potential predictor of sensitivity to the treatment
of carcinoma, as shown by various in vitro studies (17, 18),
thus CD105 could be used as a potential therapy in cancer.
Currently, CD105 is under phase 1 and phase 2 clinical trial
in cancer patients (our and Seon et al.’s unpublished data). 
CD105 has two isoforms, long-form L-CD105 and short-
form S-CD105 (19), both of which bind to TGF-β1 and TGF-
β3. These two isoforms have contrasting roles in angiogenesis
with L-CD105 being pro-angiogenic and S-CD105 inhibiting
angiogenesis (20). Since L-CD105 is expressed at a markedly
higher level than S-CD105 in ECs, the overall balance tends
towards a pro-angiogenic phenotype in vivo (21).
The expression of CD105 on ECs and other cells is up-
regulated by both TGF-β and hypoxia (22), but their additive
effect is substantially greater than by themselves (23). Vascular
lesions (telangiectasia and arteriovenous malformations) in
CD105 haploinsufficient hereditary hemorrhagic telangiectasia
type I (HHT1) patients are associated with a loss of the
capillary network (1, 24). The association of mutations of the
CD105 gene with HHT1 indicates the importance of CD105
for normal vascular architecture. Knockout mice for CD105 die
in utero due to defective angiogenesis (1, 25).
Our previous and other studies have shown that CD105 is
a critical marker for the quantification of microvessel density
staining in numerous types of human tumours (3, 26-31) and
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is involved in TGF-β1 induced cell signal transduction (1, 32-
35). Although, the intracellular mechanisms by which and how
CD105 modulates TGF-β1 signalling have been extensively
studied, they need further clarification (7, 9, 36-46).
The roles played by CD105 in the tumour angiogenesis
and the development had been widely studied (47-51).
Previous studies have shown that CD105 was expressed in
many types of tumours (22, 52-56). 
The microenvironment of solid tumours consists of
heterogeneous cell types such as endothelial (ECs),
inflammatory (T cell and macrophages) mesenchymal stem
(MSCs), fibroblasts, myofibroblasts (also called cancer-
associated fibroblasts, CAFs), determines cancer prognosis
(57-60). Most importantly apart from ECs, CD105 is also
expressed on MSCs, CAFs and some subtypes of T-cells, is
involved in their functional regulation and is a determinant of
cancer development (45, 61). In an attempt to examine the role
of CD105 on tumour angiogenesis and its effect on other cell
types that are within the cancer microenvironment, we could
not use human umbilical vein endothelial cells (HUVECs) or
CAFs as a model system to overexpress CD105, because both
these cell types express CD105 (3, 62, 63). In this study, we
chose to use rat myoblasts stably transfected with human
CD105 to determine the downstream signalling mechanisms
of CD105. This may lead to designing anticancer approaches.
We found that overexpression of L-CD105 in rat myoblasts
induced growth inhibition and reduced ERK phosphorylation.
This finding is consistent with the previous publications that
CD105 expression in cancer cells inhibits their growth and
metastasis (64-67).
Materials and Methods
Stable human CD105 transfection in rat myoblasts. Preparation of
stable rat myoblast CD105 transfectants expressing human L-
CD105, S-CD105 and control mock transfectants was as described
(68). No significant differences were observed between parental and
mock transfectants in biochemical, functional and other studies (32).
Cell culture of human CD105 transfectants. The transfected rat
myoblasts; mock (L6M), L-CD105 (L6L) and S-CD105 (L6S)
transfectants were cultured in six-well plates (2×105 cells/well) as
previously described (32). The mock (L6M), L- and S-CD105
transfectants (L6L, L6S) were initially seeded in six-well plates
(2×105 cells/well) and utilised for western blotting as described
previously (69).
Quantification of cell viability. Human CD105 transfected rat
myoblasts were seeded and maintained in six-well plates at 1×105
cells/well (32). Total cell counts were undertaken at 24 h, 48 h and
72 h and following trypsinisation using a Coulter Counter (Beckman
Coulter, High Wycombe, UK).
Immediately after the cell counting, their viability was
ascertained using 0.04% trypan blue. Four hundred cells were
counted for each condition at every time point and the number of
dead cells was expressed as a percentage of the total cell
population. There were no significant differences in cell viabilities
amongst the three kinds of transfected rat myoblasts (data not
included).
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Table I. List of selected proteins identified by Kinexus phospho-protein array.
Protein name                                                          Abbreviation                 L6M               L6L                 L6S               T-L6M            T-L6L           T-L6S
                                                                                    epitope
Cyclin-dependent protein-serine                              CDK1/2                     100%            –16%                18%               164%               54%             85%
kinase 1/2                                                                     Y15
Extracellular regulated protein-serine                       ERK1                      100%            –89%              –70%               133%             –18%             24%
kinase 1 (p44 MAP kinase)                                 T202+Y204
Extracellular regulated protein-serine                       ERK2                      100%            –70%                11%               123%             –52%             57%
kinase 2 (p42 MAP kinase)                                  T185+Y187
c-Jun proto-oncogene-encoded                                   c-Jun                       100%            –88%              –67%               148%             –44%           –37%
AP1 transcription factor                                               S73
MAPK/ERK protein-serine                                      MEK1/2                    100%            –55%              –81%               135%               –5%           –46%
kinase 1/2 (MKK1/2)                                             S217/S221                       
MAP kinase protein-serine                                      MEK3/6                    100%            –63%              –53%               134%             –31%           –21%
kinase 3/6 (MKK3/6)                                             S189/S207
Protein-serine                                                             PKC α                      100%            254%              133%                 32%             259%           283%
kinase C α 
Raf1 proto-oncogene-encoded                                Raf1 (60)                    100%              13%              159%                 66%             144%           236%
protein-serine kinase (S259)
Src proto-oncogene-encoded                                    Src (46)                     100%                7%                17%               131%             169%           172%
protein-tyrosine kinase (Y529)
T: TGF-β1; L6M: Mock transfectants; L6L: L-CD105 transfectants; L6S: S-CD105 transfectants; T-L6M: TGF-β1 treated mock transfectants; T-
L6L: TGF-β1 treated L-CD105 transfectants; T-L6S: TGF-β1 treated S-CD105 transfectants. The results from Kinexus protein array were shown
and the proteins were normalised as count per minute (CPM). The changes of 25% were as significant.
Cell proliferation following stimulation with TGF-β1. Human
CD105 transfectants were cultured in six-well plates at a density of
1×105 cells/well in 2 ml complete Dulbecco’s Modified Eagle
Medium (DMEM) containing TGF-β1 (5 ng/ml, R&D Systems,
Oxford, UK), in a humidified 5% CO2/air atmosphere incubator at
37˚C. After 48 h following trypsinisation, the cell numbers were
counted using a Coulter Counter (Beckman Coulter, High
Wycombe, UK).
Cell culture and protein extraction for western blot. L6M, L6L and
L6S cells were seeded at 2×105/well in DMEM supplemented with
10% FBS, 2 mM L-glutamine and 1% antibiotics (10 U/ml
penicillin and 100 μg/ml streptomycin) in 6-well plate and
incubated in a water-saturated, 5% CO2 incubator at 37˚C. For each
experiment, the cells were starved in serum poor medium (cells
were incubated in 1% FBS DMEM for 24 h) prior to the assay.
For the TGF-β1 treatment study, the un-confluent starved cells
were treated with TGF-β1 (5 ng/ml, R&D Systems, Oxford, UK)
for 5 min, 10 min and 30 min respectively. The cells were washed
twice with ice-cold PBS and then were lysed by adding ice-cold
Kinexus Lysis Buffer (Kinexus service, Vancouver, British
Columbia, Canada) 300 μl/well and incubated on ice for 1 min and
then using a cell scraper to collect the cell lysates. After that, the
cell lysates were transferred into a 1.5 ml Eppendorf tube and
continued incubated on ice for 20 min. During the incubation, the
cell lysates were sonicated every 2 min. Subsequently, the lysates
were centrifuged at 10,000 × g for 10 min at 4˚C. The supernatants
were collected, and aliquots stored at –80˚C for later use.
Protein estimation and western blotting. Protein concentration was
estimated using a BCA Protein Reagents (ThermoFisher Scientific,
Cambridge, UK). The protein samples (30 μg of each) were
processed under reducing conditions by adding equal volumes of 2-
fold concentrated sample buffer and then subjected to 10% SDS-
PAGE (70).
Kinetworks™ Phospho-site protein Screen assay. Human CD105
transfected rat myoblasts were seeded (4×105 cells/dish) in 10 ml
cell culture dishes (32). Sub-confluent cells were treated with TGF-
β1 (5 ng/ml) for 10 min and lysed with 1 ml of ice-cold cell lysis
buffer (Kinexus, Vancouver, British Columbia, Canada). All cell
lysates were sonicated twice (15 sec each time), and then incubated
on ice for 20 min before ultracentrifugation for 30 min at 1×105 g
at 4˚C. The resulting supernatant fractions were collected and
assayed for protein concentration using a BCA Protein Reagents
(ThermoFisher Scientific, Cambridge, UK) and adjusted to 1 mg/ml
prior to use in the KPSS-1.3 protein array (Table I).
Statistical analysis. All data are presented as the mean±standard
deviation from at least 3 independent experiments and were
analysed using GraphPad Prism software version 7.0 for Windows
(GraphPad Software, San Diego, CA, USA). The values were
compared using a paired Student’s t-test. The differences at p<0.05
were considered statistically significant.
Results
Western blotting showed that human CD105 was expressed
in both L6L and L6S cells but not in mock cells (Figure 1),
wherein β-actin was used as a loading control. Figure 1 is
representative of two separate experiments that gave similar
results. All the experiments were repeated at least twice.
Cell growth studies demonstrated that in complete
medium, L6M control cells grew significantly faster than
L6L cells (n=3, p<0.05; Figure 2) at 24 h, 48 h and 72 h. In
contrast, L6S cell growth was not significantly (p>0.05)
different to control L6M cells on any of the time points. 
Furthermore, L6M cells in the presence and absence of
TGF-β1 grew significantly faster than L6L cells over 72 h
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Figure 1. Western blotting showing that human CD105 were transfected into rat myoblasts successfully, whereas L-CD105 protein was overexpressed
in L6L and S-CD105 protein was overexpressed L6S cells, but there was no CD105 expression in mock cells. β-actin was used as a loading control.
The data are representative of two experiments of duplicate samples. M: Mock, L6M cells; L: L6L cells; S: L6S cells.
(n=3, p<0.05; Figure 3). The proliferation of L6L cells
following TGF-β1 treatment was almost completely nullified
within 72 h (n=3, p<0.05) compared to control mock cells
without TGF-β1 stimulation (Figure 3). Figure 3 is
representative of two separate experiments, utilising
triplicate samples.
Cell signal transduction activation was analysed by a
Kinexus phospho-protein (KPSS−1.3) array. De-regulated
phosphorylated proteins were identified and showed a
notable reduction of phospho-ERK1/2, phospho-MEK1/2,
and phospho-c-Jun in L-CD105 transfectants (L6L)
compared to mock cells (L6M). Whilst, all these proteins
were less decreased in S-CD105 transfectants (L6S)
compared to L-CD105 transfectants (L6L). Figure 4 shows
phospho-ERK1/2, phospho-MEK1/2, and phospho-c-Jun
expression were up-regulated after TGF- β1 treatment in
both L-CD105 and S-CD105 transfectants. The total proteins
extracted from human CD105 transfected rat myoblasts in
the Kinexus phospho-protein western screening (KPSS−1.3)
array were detected by 10% SDS-PAGE, with β-actin used
as a loading control. In all cases, data were obtained from
duplicate spots in the Kinexus array.
ERK1/2 is implicated in cell signalling via the TGF-β1
receptor. Western blotting results (Figure 5) showed the basal
level of p-ERK1/2 in L6M cells was substantially higher
than in both L6L and L6S cells. The p-ERK1/2 level was
higher in L6S cells than in L6L cells. Figure 4 shows p-
ERK1/2 and p-MEK1/2 were significantly increased in both
L6M and L6S cells. p-c-Jun1/2/3 was increased in TGF-β1
treated L6M cells, but less so in TGF-β1 treated L6L cells.
p-c-Jun1/2/3 expression was at lower levels either in the
presence or in the absence of TGF-β1 in both L6L and L6S
ells, but the L6L cells had decreased more than the L6S
cells. In all cases, β-actin was used as a loading control and
data represent results from two separate experiments of
duplicate samples.
To examine ERK1/2 expression associated with TGF-β1
signalling in transfected rat myoblasts, the cell lines were
stimulated with TGF-β1 at various times. Following
treatment with human TGF-β1, the ERK1/2 was activated
within 10 min in mock (L6M) cells (Figure 5A). In TGF-β1
treated L6L cells, p-ERK1/2 increased within 5 min and
peaked at 10 min, although it remained significantly lower
(p<0.05) than in mock cells. After peaking at 10 min, p-
ERK1/2 declined gradually in L6L cells treated with TGF-
β1 but remained above basal levels (untreated L6L cells)
after 8 h (data not shown). Similarly in TGF-β1 treated L6S
cells (where the basal levels were higher than in L6L cells
but lower than in mock cells),  p-ERK1/2 increased at 5 min,
peaked at 10 min, and thereafter began to decline in a similar
pattern to that observed in L-CD105 transfected cells. The
results showed that the relative increase in ERK1/2
activation was lower in L-CD105 transfectants compared
with S-CD105 transfectants and mock cells.
ANTICANCER RESEARCH 41: 1219-1229 (2021)
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Figure 3. Cell proliferation assay displaying a significant inhibition in
L6L cells after 72 h (significant, n=3, p<0.05) with and without TGF-
b1 treatment compared to control (mock cells without TGF-b1
treatment). Data represent results from three experiments, with samples
measured in triplicate for each experiment. M: L6M cells; L: L6L cells;
S: L6S cells; TM: TGF-b1 treated L6M cells; TL: TGF-b1 treated L6L
cells; TS: TGF-b1 treated L6S cells.
Figure 2. Cell proliferation assay showing a significant decrease in L6L
after 24 h and 72 h of treatment (n=3; p<0.05). However, there was
only a slight non-significant decrease in L6S cells, compared to L6M
cells. The data represent results from three experiments, with samples
measured in triplicate for each experiment. M: L6M cells; L: L6L cells;
S: L6S cells.
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Figure 4. Proteomics study showing phosphorylated proteins in L6M, L6L, and L6S cells. Since CD105 appears to influence the activation of multiple
signalling pathways, its effects on intracellular signal transduction in rat myoblast human CD105 transfectants were analysed using a Kinexus
phospho-protein Western screening (KPSS-1.3) array. De-regulated phospho-proteins in both L-CD105 and S-CD105 transfectants were observed
compared to control (mock transfectants). There was a significant reduction (n=3, p<0.05) in p-ERK1/2, p-MEK1/2, and p-c-Jun1/2/3 in L6L,
compared to mock cells (control), whereas L6S cells were less affected. After TGF-β1 treatment for 10 min, the p-ERK1/2, MEK1/2 and p-c-Jun
were up-regulated in L6M and L6S but were less in L6L cells. The count per minute from Kinexus highlighted significant differences among the
L6M, L6L, and L6S cells. The data represent a single experiment with proteins separated and analysed in duplicate. M: L6M cells; L: L6L cells; S:
L6S cells; TM: TGF-b1 treated L6M cells; TL: TGF-b1 treated L6L cells; TS: TGF-b1 treated L6S cells.
Discussion 
CD105 is predominantly expressed in angiogenic vascular
ECs in different types of cancers. It forms a complex with
the TGF-β receptor and is able to modify TGF-β1-mediated
signalling pathways (1, 71). Like previous studies, Ilhan et
al. concluded that overexpression of CD105 in colorectal
cancers was associated with tumour angiogenesis and poor
prognosis (8). However, the mechanism through which
CD105 interacts with TGF-β1 and how it interacts with
intracellular signalling pathways is not fully elucidated.
An important finding emerging from this study is that
mitogenesis/cell proliferation was reduced in both L- and S-
CD105 transfectants compared to mock cells. Unexpectantly,
L6L cells grew significantly more slowly than L6S cells, that
contrasts with a previous publication (72). Further, TGF-β1
induced proliferation of L-CD105 transfectants. We
hypothesise that chronic overexpression of this receptor
could lead to antagonistic or receptor feedback mechanisms
which reduce the expression of phospho-ERK1/2 in these
cells. In our phospho-protein study, ERK1/2, MEK1/2, and
c-Jun1/2/3 were down-regulated in the L-CD105 but less so
in S-CD105 transfectants. As ERK is a key pro-mitogenic
signalling intermediate, reduction in its expression/activation
normally leads to reduced cell proliferation. This explains
the fact that compared to L6M (mock transfectants), L6L
cells grew more slowly than L6S cells.
This is the first study to show that both ERK, MEK and
c-Jun phospho-protein expression is suppressed in rat
myoblast CD105 transfectants. Specifically, western blot
analysis revealed that phospho-ERK1/2 was significantly
inhibited in both L-CD105 and S-CD105 transfectants. As
previously reported, c-Jun plays an essential role in
organogenesis during mouse embryonic development by
regulating cell survival, apoptosis, and proliferation (73, 74).
Therefore, it is possible that inhibition of the c-Jun pathway
may influence proliferation in L-CD105 transfectants.
Although the phosphorylation of ERK remained inducible
in CD105 transfected rat myoblasts after stimulation by
TGF-β1, the presence of the L-CD105 isoform significantly
attenuated this response (12, 14). Chronic activation of the
TGF-β1 receptor by L-CD105 may have resulted in self-
down-regulation or indeed induction in the activation of key
signalling intermediates such as MEK, responsible for ERK
ANTICANCER RESEARCH 41: 1219-1229 (2021)
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Figure 5. Western blot results demonstrates the phosphorylation of ERK1/2 (A) in L6L, L6S and L6M cells. The bar graph (B) suggests that the
phosphorylation of ERK1/2 was notably reduced in L6L after TGF-b1 treatment, while weaker inhibition was observed in L6S cells compared to
L6M (control) cells. β-actin was used as a loading control. The basal levels of p-ERK1/2 in L6M cells was much higher than that in L6L cells.
Following treatment with TGF-b1, p-ERK1/2 in L6M cells increased after 5 min and peaked after 10 min, showing similar levels to those in L6S.
In L6L cells, after TGF-b1 treatment, p-ERK1/2 was also noticeably increased at 5 min, peaked at 10 min (but remained much lower than in L6M
cells), and thereafter declined. L6S cells showed a steady increase after TGF-β1 treatment. Data are representative of two experiments with duplicate
samples in each experiment. M: Mock, L6M cells; L: L6L cells; S: L6S cells.
phosphorylation. Taken together, these data suggest that
over-expression of CD105 in rat myoblast transfectants may
play an important role in the modulation of the ERK
signalling pathway via TGF-β1 signalling in these cells.
Previously we demonstrated that the phosphorylation of
Smad3 was inhibited by CD105, which also inhibited TGF-
β1-Smad3 signalling. Overexpression of CD105 leads to
phosphorylation of JNK, but there are no additive/synergistic
effects on the JNK phosphorylation after TGF-β1 treatment.
And CD105 may either prohibit TGF-β1/Smad3 signalling
or inhibit the transcriptional activity of Smad3 up-regulating
the phosphorylation of JNK (14). Here we found that over-
expression of CD105 is also associated with the inhibition
of p-ERK expression in rat myoblasts transfected with
human CD105, and this might either interact with smad3 or
act alone through ERK1/2. The stimulation of TGF-β1
activates the ERK MAP kinase (69), but the exact role of
ERK in the modulation of the TGF-β1 signalling pathway is
unclear (71, 75, 76). We hypothesise that the over-expression
of human L-CD105 in these cells modulates TGF-β1 induced
cell signalling and this occurs primarily through the ERK
and c-Jun signalling pathways other than the smad3 pathway,
but the detailed mechanisms need further exploration.
The decrease of p-ERK1/2 in L-CD105 transfectants may
differently influence cell signalling, depending on which
type of cell is under consideration. Although our data
demonstrate that L-CD105 modulates TGF-β1 induced cell
signalling through a pathway involving ERK-c-Jun
expression in human CD105 transfectants in vitro, further
work is required to identify other participants in TGF-β1
signalling pathway in these transfected cells. Similarly, the
reduction in c-Jun expression could inhibit Smad 2/3
phosphorylation, and vice versa, the activation of c-Jun
stimulated by TGF-β1 can induce the phosphorylation of
Smad 2/3 both in vivo and in vitro (76, 77).
In summary, we demonstrated that the phosphorylation of
ERK is chronically decreased in the L-CD105 transfectants. The
two isoforms of the human CD105 result in differences in gene
Liu et al: CD105 Affects MAPKs 
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Figure 6. Schematic diagram representation of the TGF-β1/ERK/c-Jun pathway regulation by the long and short form of CD105 that ultimately
determines endothelial cell proliferation, differentiation and survival. TGF-β1 stimulates ERK in the cell signalling pathway. Activation of the ERK
pathway is most often associated with cell proliferation and cell survival. Well-characterized inhibitors of Raf-1 and MEK1/2 and the interaction
of CD105 and TGF-β1 in cell signalling pathways are highlighted. Chronic overexpression of L-CD105 may play a negative role in TGF-β1 induced
MAPK signalling pathway in human CD105 transfected rat myoblasts by a negative feedback mechanism or over-stimulation of ERK1/2
phosphorylation/activation [for more details see reference (78)]. 
expression, in binding and activating the target genes and/or
proteins, as well as in the regulation of cell mitogenesis (20).
In conclusion, CD105 modulates cell growth and TGF-β1
induced cell signalling through a pathway involving ERK-c-
Jun expression in human CD105 transfectants in vitro and
that over-expression of L-form of CD105 may inhibit cell
growth by modulating phosphorylation/activation of the
ERK/c-Jun map kinase pathways (Figure 6).
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